Eczema Study

(Vanda Pharmaceuticals, 8 Weeks)

Sadick Research Group is conducting a clinical study of adult patients receiving an oral medication for atopic dermatitis (eczema). 

Phase: 3
Gender: Male and Female
Minimum Age: 18 Years Old
Maximum Age: 70 Years Old
Facility Type: Outpatient
Stipend Range: Up to $300 Upon Study Completion
Study Length: 8 Weeks
Sponsor: Vanda Pharmaceuticals

This is a double-blind, randomized, placebo-controlled study to assess the efficacy & safety of tradipitant in reducing chronic pruritus (itching) in adults with atopic dermatitis (eczema).  All enrolled subjects will receive oral medication to be taken twice daily for 8 weeks. There are 6 office visits throughout the study which may include a physical exam, blood draws, urine sampling, assessments by qualified professionals and other assessments which will be reviewed in detail at your screening visit. All services are provided at no cost.

Eligible male and female participants will be 18 years of age or older, have a diagnosis of atopic dermatitis with treatment resistant pruritus (i.e. pruritus (itching) duration of >6 weeks despite the use of antihistamine or corticosteroids). Female subjects cannot plan to be pregnant or breast feeding during the study. Subjects must be available for the 6 office visits during the study and be willing to comply with all study instructions. Several other restrictions and criteria may apply that the study doctor will review with you to determine if you qualify to enter the study.

• Physical exam and assessments of study condition to be provided at no cost by an experienced provider. 
• No insurance necessary.
• Compensation will be provided at the end of study participation.